Zentalis Pharmaceuticals, Inc.
ZNTL · XNASCIK 1725160fmd_01SVZGKY0MQJQN19A11R1SYCNDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 31 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 0 | 0 | 67 | 0 |
| Research and development | 38 | 85 | 176 | 173 | 190 | 168 | 107 |
| Total operating expenses | 47 | 119 | 217 | 227 | 300 | 259 | 153 |
| Operating income | (47) | (119) | (217) | (227) | (300) | (191) | (153) |
| Income before taxes | (46) | (118) | (166) | (238) | (293) | (166) | (137) |
| Income tax expense | 0 | 0 | (0) | (0) | (1) | 0 | 0 |
| Net income from continuing operations | (46) | (119) | (166) | (237) | (292) | (166) | (137) |
| Net income | (46) | (118) | (159) | (237) | (292) | (166) | (137) |